| epirubicin / Generic mfg. |
| Completed | 2a | 137 | Europe | Myelo001, Placebo | Myelo Therapeutics GmbH | Chemotherapy-Induced Neutropenia, Myelosuppression, Breast Cancer | 11/17 | 11/17 | | |
NCT00256360 / 2005-001876-11: Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer |
|
|
| Completed | 2 | 117 | Europe | dose dense with neulasta | Universitaire Ziekenhuizen KU Leuven, St-Augustinus Wilrijk | Breast Cancer | | 05/06 | | |
NCT00286819: Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer |
|
|
| Completed | 2 | 50 | Europe | the FEC75 and 95 regimen | Central European Cooperative Oncology Group | Breast Cancer | | 09/06 | | |
NCT02119715: A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy |
|
|
| Completed | 2 | 182 | RoW | Pegylated rhG-CSF 100μg/kg, HHPG-19K 100µg/kg, Pegylated rhG-CSF:150 μg/kg, HHPG-19K 150μg/kg, rhG-CSF 5 μg/kg/day, Jie Xin 5 μg/kg/day | Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer, Neutropenia, Febrile Neutropenia | 08/12 | 12/12 | | |
| Completed | 2 | 50 | RoW | DBD, Danggui Buxue Decoction, Epirubicin, Cyclophosphamide, Docetaxel | Shanghai Jiao Tong University School of Medicine | Grade 3/4 Neutropenia, Febrile Neutropenia | 08/15 | 10/15 | | |
NCT03314805: PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy |
|
|
| Completed | 2 | 67 | RoW | Astragalus polysaccharides 500 mg, PG2 Lyo. Injection 500 mg, Placebo, EC Chemotherapy | PhytoHealth Corporation | Cancer-related Fatigue, Neutropenia, Malignant | 05/21 | 08/21 | | |
| Recruiting | 2 | 45 | Europe | Epirubicin, Placebo | Jena University Hospital, Ruhr University of Bochum, University Medicine Greifswald | Sepsis | 10/24 | 12/24 | | |
NCT05862610: The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC |
|
|
| Not yet recruiting | 2 | 150 | NA | Trilaciclib plus chemotherapy, Trilaciclib+AC-T, Chemotherapy, AC-T | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Neoplasm | 12/26 | 06/27 | | |
SMA-BC-002, NCT05978648: Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy |
|
|
| Recruiting | 2 | 116 | RoW | Trilaciclib, COSELA®, G1T28, Epirubicin, Cyclophosphamide, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab | wang shusen | Breast Neoplasms | 12/26 | 12/27 | | |
NCT00002866: Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 50 | Canada | filgrastim, docetaxel, epirubicin hydrochloride | NCIC Clinical Trials Group | Breast Cancer, Neutropenia | 07/05 | 12/09 | | |
